What this site tracks first
The first layer is always current product information. That means the current Wegovy label, the current Ozempic label, and the main warnings or precautions that affect GI injuries, pregnancy, retinopathy, thyroid warnings, pancreatitis, gallbladder disease, and delayed gastric emptying.
After labeling, the next layer is public litigation structure, regulator actions, and trials or peer-reviewed studies that materially change how a topic should be described. That order matters because many public GLP-1 pages still mix old warnings, new warnings, and unsupported claims together.
Which topics are moving fastest right now
Severe GI injury remains the biggest public topic by volume. Gastroparesis, persistent vomiting, dehydration, bowel-obstruction questions, pancreatitis, and gallbladder disease all sit in or around that cluster, but each one needs cleaner medical distinctions than most generic lawsuit pages provide.
The vision side is the other major current topic. NAION is now significant enough that it deserves its own page because current ophthalmology research, EMA's 2025 decision, and the separate NAION MDL all changed the public landscape.
The current court and regulator picture
As of April 1, 2026, the federal GLP-1 MDL picture includes the larger GI-injury MDL and the newer NAION vision-loss MDL. That means current public content should stop acting like every GLP-1 claim belongs in one giant undifferentiated bucket.
Regulators are moving too. FDA removed suicidality warning language from the obesity GLP-1 labels in January 2026, and FDA separately announced action against non-FDA-approved GLP-1 products in February 2026. Both developments matter because they change what a careful page should say and what it should avoid saying.
Trials and studies worth watching
ClinicalTrials.gov entries are useful because they show where the medical conversation may move next. The most relevant current entries for this site are the studies on gastric contents, semaglutide-induced gastric retention, and reproductive or IVF questions.
Peer-reviewed ophthalmology work matters too. The current NAION literature is one of the clearest examples of a topic moving from a niche question into something regulators, courts, and serious publishers all have to account for.
Why approved and non-approved products need to stay separate
Current FDA communications make clear that non-FDA-approved GLP-1 products and misleading compounded-product marketing create a different problem from the approved semaglutide-label discussion. That distinction matters because public reports about compounded products, salts, counterfeits, or dosing errors should not be automatically folded into claims about the approved brand-name drugs.
For a serious site, that means pages about approved semaglutide products need to stay anchored to the approved labels, while any page about compounded or non-approved products should be explicit about that difference.